نتایج جستجو برای: subutex

تعداد نتایج: 113  

2012
V. Marmarelis S. Hadjiagapis M. Orme V. Marmarelis

S45 Fallenberg E.M.: Advisory Board; Bayer. Research/Grant Support; GE Healthcare, Siemens Healthcare, Bayer. Speaker; GE Healthcare, Siemens Healthcare, Bayer. Froehlich J.M.: Consultant; Guerbet. Frydrychowicz A.: Research/Grant Support; Scientific stipend Bracco Diagnostics. Other; The University of Wisconsin Madison receives research support from GE Healthcare. Fürst S.: Employee; B.W. Jako...

Journal: :Chest 2010
Seigo Kitada Kazuo Kobayashi Yukiko Nishiuchi Kenji Fushitani Kenji Yoshimura Yoshitaka Tateishi Keisuke Miki Mari Miki Hisako Hashimoto Masaharu Motone Takeya Fujikawa Toru Hiraga Ryoji Maekura

Affi liations: From the Department of Pharmacy (Drs Ogale and Sullivan), University of Washington; the Center for Management of Complex Chronic Care (Dr Lee), Edward Hines Jr VA Hospital; and the Center for Pharmacoeconomic Research, Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL. Dr Ogale is currently at Genentech, Inc. Financial nonfi nancial disclosures: The ...

2014
Nobuya Inagaki Kohjiro Ueki Yukio Tanizawa Hirotaka Watada Jiro Nakamura Yuichiro Yamada Iichiro Shimomura Rimei Nishimura Tsutomu Yamazaki Takashi Kadowaki

INTRODUCTION Dipeptidyl peptidase-4 (DPP-4) inhibitors including alogliptin are categorised as a newer class of oral hypoglycaemic, antidiabetic drugs to suppress the degradation of incretin hormones ((glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by DPP-4. We have scheduled a large-scale, multicentre, prospective, observational study (Japan-Based clini...

Journal: :The Journal of Automatic Chemistry 1992
Eugene McGonigle

s of papers presented at the International Symposium on Laboratory Automation and Robotics (October 1992) Keynote 1: Practical aspects of laboratory automation in pharmaceutical development Eugene J. McGonigle, Schering-Plough Research Institute, Kenilworth, NJ An early perception of laboratory automation was ’automated analysis’ and its focus on the manipulative aspects of analytical chemistry...

2014

Mechanism of Action: Dolutegravir inhibits the catalytic activity of HIV integrase, which is an HIV encoded enzyme required for viral replication. Integrase is one of the three HIV-1 enzymes required for viral replication. Integration of HIV into cellular DNA is a multi-step process. First, the assembly of integrase in a stable complex with the viral DNA occurs. Second, the terminal dinucleotid...

Journal: :The New England journal of medicine 2011
Bruce R Bacon Stuart C Gordon Eric Lawitz Patrick Marcellin John M Vierling Stefan Zeuzem Fred Poordad Zachary D Goodman Heather L Sings Navdeep Boparai Margaret Burroughs Clifford A Brass Janice K Albrecht Rafael Esteban

BACKGROUND In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal. Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an additional treatment. METHODS To assess the effect of the combination of ...

2014
Jong Man Kim Choon Hyuck David Kwon Ik Jin Yun Kwang-Woong Lee Hee Chul Yu Kyung-Suk Suh Jae-Won Joh Baik Hwan Cho

PURPOSE Generic substitution of brand-name medications can lead to significant cost savings and is an accepted medical practice. This study evaluated clinical and safety outcomes among liver transplant recipients whose mycophenolate mofetil (MMF) was converted from the brand-name formulation (Cellcept) to a generic formulation (My-rept). METHODS Clinical data from multiple centers were prospe...

Journal: :Antimicrobial agents and chemotherapy 2014
Eisuke Murakami Michio Imamura C Nelson Hayes Hiromi Abe Nobuhiko Hiraga Yoji Honda Atsushi Ono Keiichi Kosaka Tomokazu Kawaoka Masataka Tsuge Hiroshi Aikata Shoichi Takahashi Daiki Miki Hidenori Ochi Hirotaka Matsui Akinori Kanai Toshiya Inaba Fiona McPhee Kazuaki Chayama

Direct-acting antivirals (DAAs) are either part of the current standard of care or are in advanced clinical development for the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1, but concern exists with respect to the patients who fail these regimens with emergent drug-resistant variants. In the present study, ultradeep sequencing was performed to analyze resist...

Journal: :The Lancet. Oncology 2009
Peter Kenemans Nigel J Bundred Jean-Michel Foidart Ernst Kubista Bo von Schoultz Piero Sismondi Rena Vassilopoulou-Sellin Cheng Har Yip Jan Egberts Mirjam Mol-Arts Roel Mulder Steve van Os Matthias W Beckmann

BACKGROUND Vasomotor symptoms and bone loss are complications frequently induced by adjuvant treatment for breast cancer. Tibolone prevents both side-effects, but its effect on cancer recurrence is unknown. The aim of this study was to show non-inferiority of tibolone to placebo regarding risk of recurrence in breast-cancer patients with climacteric complaints. METHODS Between July 11, 2002, ...

Journal: :Journal of managed care pharmacy : JMCP 2007
Elan Rubinstein Frederic R Curtiss

A colorful ruling by federal U.S. District Court Judge Patti B. Saris (Boston) dated June 21, 2007, proclaimed that some pharmaceutical manufacturers had been “unscrupulously taking advantage of the flawed AWP (average wholesale price) system . . . by establishing secret mega-spreads far beyond the standard industry markup,” describing this behavior as “unethical and oppressive.” The case invol...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید